The GFT505 study in NASH failed, analysts said. That's bad for Genfit and good for Intercept Pharmaceuticals, which is developing a rival drug for fatty liver known as OCA.
If history repeats itself, the recent weakness in biotech stocks will end with lots more buying.
In April, Celladon is expecting results from a mid-stage study of a gene therapy aiming to improve the pumping ability of the heart in patients with advanced heart failure.
Biotech CEOs are supposed to be cheerleaders for their stock, so it's noteworthy when a CEO's pocketbook indicates otherwise.
Biotech stocks may or may not be in a bubble, but investors are definitely worried about sky-high valuations.
Vertex disclosed some new phase IIb study results that raise concerns VX-661 may not be as potent as previously hoped.
Biogen shares are up on strong Alzheimer's drug data, but is the biotech bull market making investors forget about risk?
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
Biogen Idec's drug BIIB037 slowed cognitive decline and reduced brain plaques in Alzheimer's patients.
Amicus will seek accelerated approval in the U.S. for its Fabry disease therapy in the second half of the year -- sooner than many investors expected.